Core Insights - Strong Brain Technology, a brain-computer interface "unicorn," recently completed approximately 2 billion yuan in financing, making it the second-largest financing in the global brain-computer interface sector, following Neuralink [1] - The financing round attracted prestigious investors, including IDG Capital, Huaden International founded by Intel CEO Chen Lifeng, and several technology and education companies [1] - The brain-computer interface sector has seen a surge in secondary capital, with the sector's stocks rising over 20% in the last three trading days [1] Company Overview - Founded in 2015, Strong Brain Technology is recognized alongside innovative companies like DeepSeek and Yuzhu Technology as part of the "Hangzhou Six Little Dragons" [1] - Unlike Neuralink, Strong Brain Technology focuses on the development of non-invasive brain-computer interface technology [1] - The company's products span rehabilitation medicine, smart health, and intelligent education, with FDA and CE certifications obtained [1] Product and Market Potential - The core product, "Super Sensor," can detect weak brain electrical signals without invasive procedures, converting them into neural signals to control external devices [1] - The product currently assists individuals with physical disabilities in performing activities like running and complex sports [2] - Strong Brain Technology aims to help 1 million disabled individuals regain mobility and assist 10 million patients with Alzheimer's, autism, and insomnia over the next 5-10 years [2] Financial and Investment Highlights - Strong Brain Technology has attracted significant investment since its inception, completing multiple funding rounds, including a $400 million Series A in 2019 and subsequent rounds totaling $30 million and $20 million [2] - As of 2024, the company's valuation stands at 8.5 billion yuan according to the Hurun Global Unicorn List [2] - The company is reportedly preparing for an IPO, potentially in Hong Kong or mainland China, after completing over $100 million in pre-IPO financing by 2025 [2] Industry Trends - According to research from Open Source Securities, brain-computer interface technology is expected to commercialize by 2026, expanding from medical necessities into AI applications and robotics [2] - The commercialization path for non-invasive products is clear, indicating significant revenue potential in the future [2]

Market Overview - The Shanghai Composite Index recorded a slight increase of 0.05%, marking a 14-day consecutive rise, while the ChiNext Index experienced a pullback after reaching a high, closing up by 0.31% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.85 trillion yuan, an increase of 476 billion yuan compared to the previous trading day, with trading volume exceeding 2.8 trillion yuan for two consecutive days [4] Sector Performance - The commercial aerospace sector showed strong activity, with over ten constituent stocks hitting the daily limit, including LeiKe Defense with six consecutive limit-ups and Goldwind Technology with two consecutive limit-ups [2] - The coal sector continued to rise, with Daewoo Energy and Shaanxi Black Cat both hitting the daily limit [2] - Semiconductor equipment stocks maintained strong performance, with Zhongwei Company and Northern Huachuang achieving significant gains and reaching historical highs [2] - The photoresist concept performed actively, with Guofeng New Materials achieving two limit-ups in three days, and Nanda Optoelectronics and Tongcheng New Materials both hitting the daily limit [2] - The controllable nuclear fusion concept showed a strong rebound, with China First Heavy Industries and China Nuclear Construction both hitting the daily limit [2] Declining Stocks - The brain-computer interface concept experienced a downturn, with Chengyitong and Aipeng Medical both declining over 10% [3] Notable Stocks - Sanhua Intelligent Control had a trading volume exceeding 18.4 billion yuan, ranking first, followed by Aerospace Development and Zhongji Xuchuang with high trading volumes [4]

Core Viewpoint - The company Aihuilong (688575.SH) is entering the brain-computer interface (BCI) sector through a strategic cooperation agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd, aiming to enhance diagnostic technology for central nervous system diseases and expand market reach [1][4]. Group 1: Strategic Cooperation - Aihuilong signed a strategic cooperation framework agreement with Brain Machine Starlink to integrate BCI technology with clinical and market resources [1]. - The company committed to leveraging its influence to enhance Brain Machine Starlink's financing and governance capabilities [2]. - The cooperation aims to develop BCI-related products and promote market expansion, although it has raised questions regarding the feasibility and synergy of the collaboration [2][12]. Group 2: Financial Performance - Aihuilong's revenue for the first three quarters of 2025 was 1.287 billion yuan, a year-on-year decline of 7.69%, with net profit dropping 72.36% to 60.42 million yuan [4]. - The company's stock price fell by 8.83% over the past year, with its market capitalization dropping to around 9 billion yuan [4]. - Despite the announcement of the BCI cooperation, the company's financial outlook remains uncertain, with no immediate impact on performance expected [10]. Group 3: Market Reaction - Following the announcement, Aihuilong's stock price initially rose by 3% but later experienced a decline [11]. - The Shanghai Stock Exchange issued an inquiry regarding the cooperation, questioning potential insider trading and requiring additional disclosures about the partnership [3][12]. - The BCI sector has seen a surge in interest, with related stocks experiencing significant gains, influenced by announcements from other companies in the field [10].

凤凰网财经讯 1月7日，沪指微涨录得14连阳，创业板指冲高回落。截至收盘，沪指涨0.05%，深成指涨 0.06%，创业板指涨0.31%。沪深两市成交额2.85万亿，较上一个交易日放量476亿，成交额连续2个交易 日超2.8万亿。 | | | | 沪深京重要指数 | | | | | --- | --- | --- | --- | --- | --- | --- | | 名称 *● | 咸新 | 张幅% | 涨跌 涨跌家数 涨速% | | 总手 | 现手 金额 | | 上证指数 | 4085.77 | 0.05 | 2.10 1029/1257 | -0.03 | 6.83 亿 | 45.2万 1.20万亿 | | 深证成指 | 14030.56 | 0.06 | 8.01 1076/1785 | -0.03 | 9.14 Z | 942万 1.66万亿 | | 北证50 | 1496.28 | 0.22 | 95/187 3.24 | 0.02 | 1035万 | 11.6万 275.48亿 | | 创业板指 | 3329.69 | 0.31 | 10.40 581/794 | -0.03 | 2.80 亿 | ...

下载财联社APP获取更多资讯 下跌方面，脑机接口概念震荡回落，诚益通、爱朋医疗跌超10%。 截至收盘，沪指涨0.05%，深成指涨0.06%，创业板指涨0.31%。 上证指数(000001) 01-07 15:06:27 沪 4085.77 +2.10 +0.05% 《 高 4098.78 成交量 6.83亿手 开 4083.84 最 昨 4083.67 收 俱 4069.44 成交额 1.20万亿 ▲ 最 分时 五日 (0) MA5:4025.36 MA10:3987.63 MA20:3934.81 不复权 4128.65 4098.78 · 4039.05 -394945 · 3800.11 3770.24 2025-12-05 2026-01-07 2025-09-30 2025-11-06 今日沪指微涨录得14连阳 ，创业板指冲高回落。沪深两市成交额2.85万亿，较上一个交易日放量476亿，成交额连续2个交易日超2.8万亿。 盘面上，市场热点快速轮动，全市场超3100只个股下跌。从板块来看， 商业航天概念反复活跃 ，十余只成分股涨停，雷科防务6连板，金风科技2连 板。煤炭板块持续拉升，大有能源、陕西黑猫 ...

Market Overview - The three major A-share indices experienced slight increases, with the Shanghai Composite Index rising by 0.05% to close at 4085 points, marking a 14-day consecutive gain [1] - The Shenzhen Component Index increased by 0.06%, while the ChiNext Index rose by 0.31% [1] - The total market turnover reached 2.88 trillion yuan, an increase of 493 billion yuan compared to the previous trading day, with nearly 3200 stocks declining [1] Sector Performance - The storage chip sector saw a significant surge in prices, leading to explosive growth, with stocks like Tongcheng New Materials and Hengkun New Materials hitting the daily limit [1] - The electronic chemicals sector also performed well, with Guanggang Gas hitting the daily limit [1] - The photolithography machine (gel) sector strengthened, with multiple stocks such as Nanda Optoelectronics reaching the daily limit [1] - The media sector experienced a rally, with stocks like Dayou Energy and Shaanxi Black Cat hitting the daily limit [1] - Other sectors with notable gains included semiconductors, controllable nuclear fusion, CPO concepts, and rare earth permanent magnets [1] Declining Sectors - The DRG/DIP concept saw a decline, with Rongke Technology hitting the 20% daily limit down [1] - The brain-computer interface sector faced a significant pullback, with stocks like Chengyitong and Aipeng Medical dropping over 10% [1] - The titanium dioxide sector weakened, with Zhenhua Holdings leading the decline [1] - Sectors such as digital currency, under-screen photography, and brokerage concepts also experienced notable declines [1]

Group 1 - The brain-computer interface sector in the A-share market experienced a significant decline, with multiple companies reporting substantial drops in their stock prices [1] - Major companies such as Mailland, Chengyitong, and Aipeng Medical saw declines exceeding 10%, while others like Leidi Ke and Weisi Medical dropped over 8% [1][2] - Several brain-computer interface concept stocks issued announcements indicating a cooling off, with companies like Aerospace Changfeng stating they have not actually engaged in related business activities [1] Group 2 - Mailland's stock fell by 11.09%, with a total market value of 54.43 billion [2] - Chengyitong's stock decreased by 10.91%, with a market capitalization of 6.731 billion [2] - Aipeng Medical's stock dropped by 10.39%, with a market value of 4.514 billion [2]

记者丨雷若馨 编辑丨孙超逸 2022年的冬季残奥会上，失去左臂及右臂大部分的运动员贾红光，佩戴着智能仿生手，通过非侵入式脑机接口技术识别大脑意图，顺利完成火炬交接和传 递。 2025年的冬天，马斯克宣布，脑机接口公司"神经连接（Neuralink）"将启动大规模脑机接口输出，并计划转向近乎全自动化手术，引爆全球医疗行业热度。 新年伊始，A股脑机接口概念板块接连两个交易日掀涨停潮，超50亿元资金流入。Wind数据显示，最近三个交易日，脑机接口指数累计涨幅超过14%。 1月7日早盘，脑机接口概念延续强势，创新医疗、南京熊猫双双3连板。 | 名称 | 现价 | 涨跌幅 ▼ | 换手率 | 市智率 | 年初至今 | | --- | --- | --- | --- | --- | --- | | 美好医疗 | 41.49 | 19.81% | 20.53% | 75.1 | 72.52% | | 创新医疗 | 28.63 | 9.99% | 1.65% | -206 | 33.10% | | 开立医疗 | 28.56 | 3.48% | 2.34% | 185 | 8.10% | | 航天长峰 | 26.15 | 2. ...

Core Viewpoint - The article highlights the rapid growth and investment potential in the brain-computer interface (BCI) sector, driven by technological advancements and significant market interest, particularly following announcements from Neuralink regarding large-scale production and automation of BCI devices [1][4][14]. Market Performance - The A-share BCI concept sector experienced a surge, with over 5 billion yuan flowing into the market, and the BCI index showing a cumulative increase of over 14% in the first three trading days of the year [1][8][11]. - Notable stocks in the BCI sector include Meihao Medical, which saw a 19.81% increase, and Innovation Medical, which rose by 9.99% [2]. Industry Overview - BCI technology connects the brain with external devices for information exchange, categorized into three types: invasive, semi-invasive, and non-invasive, each with varying levels of signal quality and risk [4]. - The healthcare sector is identified as the primary application area for BCI technology, accounting for 56% of its applications, with projections estimating the global BCI medical application market to reach $40 billion by 2030 and $145 billion by 2040 [4][6]. Policy and Development - The Chinese government has included BCI in its "14th Five-Year Plan," with goals for core technology breakthroughs by 2027 and positioning the industry among the world's leaders by 2030 [5][6]. - In 2025, several companies, including Boryeong and Ladder Medical, completed significant implantation trials, marking China's entry into clinical trials for invasive BCI after the U.S. [6]. Company Developments - Companies like Beiyikang and Aipeng Medical are actively involved in BCI, with Aipeng focusing on non-invasive technologies and partnerships for rehabilitation systems [10][12]. - Other firms, such as Xiangyu Medical and Xinwei Medical, are developing various BCI products and are expected to see rapid revenue growth in the coming years [10][12]. Investment Landscape - The BCI sector has attracted significant investment, with nearly 100 financing events in the past five years totaling over 10 billion yuan, and a notable 30% year-on-year increase in financing activities in 2025 [14]. - Analysts suggest that the BCI industry is on the verge of commercial growth, supported by policy and technological advancements, while also cautioning about the challenges of clinical validation and high costs [14][15].

Group 1 - The brain-computer interface sector experienced a significant decline in the afternoon, with companies such as Chengyitong, Aipeng Medical, and Entropy Technology dropping over 10% [1] - Other companies in the sector, including Xiangyu Medical, Mylan, and Weisi Medical, also faced notable declines [1]